dataesr/scientific-paragraphs-categorization huggingface dataset:
They should lived in Algiers and accepted medical monitoring for 2 years Chaulet 1995 Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review) Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Control 1. The same drugs as single formulations (N = 126). Doses used: isoniazid 300 mg; rifampicin 450 mg for participants weighing < 50 kg and 600 mg for ≥ 50 kg; and pyrazinamide 1500 mg for participants weighing < 50 kg and 2000 mg for ≥ 50 kg Continuation phase (20 weeks)1. 2FDCs (isoniazid and rifampicin) for all participants: 3 tablets (isoniazid 100 mg and rifampicin 150 mg per tablet) for participants weighing < 50 kg and 2 tablets (isoniazid 150 mg and rifampicin 300 mg per tablet) for participants weighing > 50 kg.
Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Notes Location: USA Setting: TB clinics Source of funding: not mentioned Comments: follow-up duration was 2 years after completion of treatment. Time of assessment of reported outcomes: "during the first 8 weeks of therapy" Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk'. Geiter 1987 (Continued) Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review) Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Outcomes reported and not used in this review 1. Unfavorable outcome: a combined endpoint of: a. bacteriological failure or relapse by 18 months after treatment initiation; b. treatment changed after 5 months because of 2 positive sputum smear results or a clinical or radiographic deterioration in the absence of bacteriological confirmation; and c. death, definitely or probably attributable to TB. 2. Favorable response: sputum culture negative at 18 months (or 24 months, if the 18 months result was unavailable). NotesTwo publications for the same clinical trial (Lienhardt 2011; Nunn 2014). All outcomes were assessed according to the data provided in Lienhardt 2011. In Nunn 2014 the assessment was done at 30 months after initiation of treatment and is the most recent publication, but the results confirm those found in Lienhardt 2011 and the trial authors suggest that the follow-up should be limited to 18 months after initiation of treatment in this kind of clinical trialsCochrane Database of Systematic Reviews and 30 months in the follow-up phase.
© 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Munteanu 2004 (Continued) All outcomes Selective reporting (re- Unclear risk There was insufficient information to permit a judgement of 'low risk' or 'high porting bias) risk'. Other bias Low risk The trial appears to be free of other sources of bias. Methods Design: RCT Generation of allocation: not stated Allocation concealment: serially numbered envelopes Blinding: not stated Duration: 1 year (from August 1986 to August 1987) Participants Number of participants: 229 randomized Males: 70% (of included population on final analysis) Inclusion criteria: new pulmonary TB patients, aged at least 15 years and weighing not less than 30 kg, without complications (TB or non-TB) that could interfere with TB treatment Exclusion criteria: participants with "poor condition or were moribund" and "cases with pleural effusion if the effusion obscured more than one third of lung field" Completeness of follow-up: 91.
Informed decisions. Better health. Cochrane Database of Systematic Reviews RCTAI 1989 (Continued) Selective reporting (re- Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk'. porting bias) Other bias Low risk The trial appears to be free of other sources of bias. Methods Design: RCT Generation of allocation sequence: "by the method of random numbers" Allocation concealment: not stated Blinding: not stated Duration: 2 years and 1 month (from October 1999 to November 2001) Participants Number of participants: 387 randomized Males: 58. 9% (ITT population)Inclusion criteria: newly diagnosed pulmonary TB adults, aged from 16 to 50 yearsExclusion criteria: not reportedCompleteness of follow-up: not reportedBaseline drug susceptibility test: initially drug resistant participants 4.
Cochrane Database of Systematic ReviewsInclusion criteria: participants aged 18 years or more with active pulmonary TB, confirmed by sputum smear or culture or both, and with no history of previous TB treatment FDCs tablets with Rifater® (isoniazid 50 mg, rifampicin 120 mg and pyrazinamide 250 mg per tablet)+ etambuthol as single-drug formulation for the first 2 months (intensive phase) followed by Rifi-nah® 150 (isoniazid 100 mg and rifampicin 150 mg per tablet) or Rifinah® 300 (isoniazid 150 mg and rifampicin 300 mg per tablet) + etambuthol as single-drug formulation for 4 months (continuation phase) (N = 57). Cochrane Library Trusted evidence. Informed decisions. Better health. Exclusion criteria: not reported Completeness of follow-up: 48. 6% (ITT population) Baseline drug susceptibility test: initially drug resistant participants 23.
5% (12/51 included in analy- sis); FDCs: 4 resistant to Z and single-drug formulations: 2 resistant to E and 6 to Z Semenova 2003 HIV status of participants: not reported Interventions Six months treatment regimen (2HRZE/4HRE) Intervention 1. Outcomes 1. Rate of disappearance of clinical symptoms of TB. 2. Sputum conversion at 4 months after initiation of treatment. 3. Cavity closure rate. 4. Adverse events: those leading to discontinuation of therapy and other adverse events. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
S Comparison 1. Fixed-dose combinations versus single-drug formulations as available data Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Analysis 1. 1 Outcome or subgroup title No. of studies No. of partici- Statistical method Effect size pants 1 Treatment failure 7 3606 Risk Ratio (M-H, Fixed, 95% CI) 1. 28 [0. 82, 2. 00] 2 Relapse 10 3621 Risk Ratio (M-H, Fixed, 95% CI) 1. 28 [1. 00, 1. 64] 3 Death 11 4800 Risk Ratio (M-H, Fixed, 95% CI) 0. 96 [0. 67, 1. 39] 4 Sputum smear or culture conver- 13 4836 Risk Ratio (M-H, Fixed, 95% CI) 1. 01 [0. 99, 1. 03] sion at 2 months of starting treat- ment 5 Sputum smear or culture conver- 7 2319 Risk Ratio (M-H, Fixed, 95% CI) 0. 99 [0. 96, 1. 02] sion at end of treatment (EOT) 6 Treatment adherence at 8 weeks 3 881 Risk Ratio (M-H, Random, 95% 1.
Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 3 Death. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Zhu 1998 0/227 0/81 Not estimable Teo 1999 8/132 6/139 10. 57% 1. 4[0. 5,3. 94] Su 2002 7/57 2/48 3. 93% 2. 95[0. 64,13. 53] Suryanto 2008 11/173 18/149 34. 99% 0. 53[0. 26,1. 08] Zaka-Ur-Rehman 2008 0/141 1/69 3. 63% 0. 16[0. 01,3. 98] Bartacek 2009 11/558 4/564 7. 2% 2. 78[0. 89,8. 68] Lienhardt 2011 4/684 7/664 12. 85% 0. 55[0. 16,1. 89] Wu 2015 6/75 8/86 13. 48% 0. 86[0. 31,2. 37] Total (95% CI) 2373 2427 100% 0. 96[0. 67,1. 39] Total events: 52 (FDCs), 60 (SDF) Heterogeneity: Tau =0; Chi =12.
21, df=9(P=0. 2); I =26. 27% Test for overall effect: Z=0. 21(P=0. 84) Favours FDCs 0. 005 0. 1 1 10 200 Favours SDF Analysis 1. 4 Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Geiter 1987 2/122 13/416 10. 67% 0. 52[0. 12,2. 29] RCTAI 1989 1/102 0/108 0. 88% 3. 17[0. 13,77. 05] Zhang 1996 2/102 1/103 1. 8% 2. 02[0. 19,21. 93] Favours FDCs 0. 005 0. 1 1 10 200 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 5 Sputum smear or culture conversion at end of treatment (EOT). Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Zhu 1998 224/227 79/81 11. 57% 1. 01[0. 97,1. 05] Su 2002 25/26 25/25 2. 58% 0. 96[0. 87,1. 07] Suryanto 2008 188/198 152/160 16. 7% 1[0. 95,1. 05] Bartacek 2009 468/582 477/577 47. 59% 0. 97[0. 92,1. 03] Wu 2015 49/49 49/49 4. 92% 1[0. 96,1. 04] Total (95% CI) 1250 1069 100% 0. 99[0. 96,1. 02] Total events: 1119 (FDCs), 954 (SDF) Heterogeneity: Tau =0; Chi =4. 42, df=6(P=0. 62); I =0% Test for overall effect: Z=0. 77(P=0. 44) Favours SDF 1 1 1 Favours FDCs Analysis 1.
6 Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI RCTAI 1989 64/66 71/74 6. 65% 1. 01[0. 95,1. 08] Zhang 1996 101/102 101/103 9. 99% 1. 01[0. 98,1. 04] Favours SDF 1 1 1 Favours FDCs Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
7. Comparison 1 Fixed-dose combinations versus single-drug formulations as available data, Outcome 7 Treatment adherence at EOT. Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Analysis 1. 8. Geiter 1987 118/122 408/416 45. 39% 0. 99[0. 95,1. 02] RCTAI 1989 35/95 37/101 8. 8% 1. 01[0. 7,1. 45] Chaulet 1995 44/44 50/52 11. 38% 1. 04[0. 97,1. 11] Zhu 1998 247/258 83/90 30. 19% 1. 04[0. 97,1. 11] Su 2002 18/26 17/25 4. 25% 1. 02[0. 7,1. 48] Total (95% CI) 545 684 100% 1. 01[0. 97,1. 06] Total events: 462 (FDCs), 595 (SDF) Heterogeneity: Tau =0; Chi =3. 1, df=4(P=0. 54); I =0% Test for overall effect: Z=0. 47(P=0. 64) Favours SDF 1 1 1 Favours FDCs Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors.
[1. 37,1. 64] Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Analysis 1. Total events: 410 (FDCs), 282 (SDF) Heterogeneity: Not applicable Test for overall effect: Z=8. 68(P<0. 0001) 1. 9. 4 Acceptable taste Bartacek 2009 402/515 298/529 100% 1. 39[1. 27,1. 51] Subtotal (95% CI) 515 529 100% 1. 39[1. 27,1. 51] Total events: 402 (FDCs), 298 (SDF) Heterogeneity: Not applicable Test for overall effect: Z=7. 27(P<0. 0001) Favours SDF 1 1 1 Favours FDCs Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
12. Comparison 1 Fixed-dose combinations versus single- drug formulations as available data, Outcome 12 Other adverse events. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Chaulet 1995 23/118 41/123 15. 77% 0. 58[0. 38,0. 91] Zhang 1996 12/102 15/103 5. 86% 0. 81[0. 4,1. 64] Zhu 1998 23/258 8/90 4. 66% 1[0. 47,2. 16] Teo 1999 45/132 45/139 17. 22% 1. 05[0. 75,1. 48] Munteanu 2004 0/20 0/20 Not estimable Zaka-Ur-Rehman 2008 40/194 26/99 13. 52% 0. 79[0. 51,1. 21] Bartacek 2009 75/558 84/564 32. 82% 0. 9[0. 68,1. 2] Lienhardt 2011 11/797 22/784 8. 71% 0. 49[0. 24,1. 01] Total (95% CI) 2301 2338 100% 0. 85[0. 72,1] Total events: 235 (FDCs), 249 (SDF) Heterogeneity: Tau =0; Chi =11.
33, df=7(P=0. 13); I =38. 19% Test for overall effect: Z=1. 97(P=0. 05) Favours FDCs 0. 2 0. 5 1 2 5 Favours SDF Comparison 2. Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Geiter 1987 6/122 8/416 1. 43% 2. 56[0. 9,7. 23] Favours FDCs 0. 2 0. 5 1 2 5 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias Outcome or subgroup title No. of studies No. of partici- pants Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Outcome or subgroup title No. of studies No. of partici- Statistical method Effect size pants 5 Sputum smear or culture conver- 7 2319 Risk Ratio (M-H, Fixed, 95% CI) 0. 99 [0. 96, 1. 02] sion at EOT 5. 1 High or unclear risk of selection 6 1160 Risk Ratio (M-H, Fixed, 95% CI) 1. 00 [0. 98, 1. 03] bias 5. 2 Low risk of selection bias 1 1159 Risk Ratio (M-H, Fixed, 95% CI) 0. 97 [0. 92, 1. 03] 6 Acquisition of drug resistance 3 491 Risk Ratio (M-H, Fixed, 95% CI) 0. 76 [0. 15, 3. 77] 6. 1 High or unclear risk of selection 2 460 Risk Ratio (M-H, Fixed, 95% CI) 0.
Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 1 Treatment failure. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Total events: 12 (FDCs), 6 (SDF) Heterogeneity: Tau =0; Chi =0. 16, df=2(P=0. 92); I =0% Test for overall effect: Z=1. 15(P=0. 25) 2. 1. 2 Low risk of selection bias Bartacek 2009 22/582 19/577 56. 91% 1. 15[0. 63,2. 1] Lienhardt 2011 10/684 8/664 24. 21% 1. 21[0. 48,3. 06] Subtotal (95% CI) 1266 1241 81. 12% 1. 17[0. 7,1. 93] Total events: 32 (FDCs), 27 (SDF) Heterogeneity: Tau =0; Chi =0. 01, df=1(P=0. 92); I =0% Test for overall effect: Z=0.
Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 2 Relapse. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Test for overall effect: Z=1. 93(P=0. 05) Test for subgroup differences: Chi =5. 28, df=1 (P=0. 02), I =81. 05% Favours FDCs 0. 1 0. 2 0. 5 1 2 5 10 Favours SDF Analysis 2. 3. Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI 2. 2. 1 High or unclear risk of selection bias RCTAI 1989 1/64 1/71 0. 96% 1. 11[0. 07,17. 37] Chaulet 1995 1/102 0/107 0. 49% 3. 15[0. 13,76. 34] Zhang 1996 2/101 2/101 2.
76, df=7(P=0. 45); I =0% Favours FDCs 0. 1 0. 2 0. 5 1 2 5 10 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Chaulet 1995 90/95 99/108 4. 67% 1. 03[0. 96,1. 11] Zhang 1996 101/102 99/103 4. 96% 1. 03[0. 99,1. 08] Zhu 1998 207/227 70/81 5. 2% 1. 06[0. 96,1. 16] Teo 1999 124/129 133/140 6. 42% 1. 01[0. 96,1. 07] Su 2002 23/26 24/25 1. 23% 0. 92[0. 79,1. 08] Munteanu 2004 14/20 15/18 0. 8% 0. 84[0. 59,1. 2] Suryanto 2008 186/198 143/160 7. 97% 1. 05[0. 99,1. 12] Zaka-Ur-Rehman 2008 187/194 94/99 6.
05, df=1 (P=0. 02), I =80. 2% Favours SDF 1 1 1 Favours FDCs Analysis 2. 5 Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI 2. 4. 1 High or unclear risk of selection bias Geiter 1987 106/122 323/416 7. 38% 1. 12[1. 03,1. 22] RCTAI 1989 67/70 73/76 3. 53% 1[0. 93,1. 07] Favours SDF 1 1 1 Favours FDCs Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 5 Sputum smear or culture conversion at EOT. Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI 2. 5. 1 High or unclear risk of selection bias Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Total events: 468 (FDCs), 477 (SDF) Heterogeneity: Not applicable Test for overall effect: Z=0. 99(P=0. 32) Total (95% CI) 1250 1069 100% 0. 99[0. 96,1. 02] Total events: 1119 (FDCs), 954 (SDF) Heterogeneity: Tau =0; Chi =4. 42, df=6(P=0. 62); I =0% Test for overall effect: Z=0.
Comparison 2 Fixed-dose combinations versus single-drug formulations as available data: sensitivity analysis by risk of bias, Outcome 7 Serious adverse events. Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Wu 2015 4/64 2/78 6. 62% 2. 44[0. 46,12. 88] Subtotal (95% CI) 380 305 15. 7% 1. 47[0. 46,4. 71] Total events: 5 (FDCs), 3 (SDF) Heterogeneity: Tau =0; Chi =2. 32, df=2(P=0. 31); I =13. 97% Test for overall effect: Z=0. 65(P=0. 52) 2. 7. 2 Low risk of selection bias Bartacek 2009 29/558 18/564 65. 78% 1. 63[0. 92,2. 9] Lienhardt 2011 4/797 5/784 18. 52% 0. 79[0. 21,2. 92] Subtotal (95% CI) 1355 1348 84. 3% 1. 44[0. 86,2. 44] Total events: 33 (FDCs), 23 (SDF) Heterogeneity: Tau =0; Chi =0.
1 High or unclear risk of selection bias Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI Test for overall effect: Z=2. 11(P=0. 03) Total (95% CI) 2760 2770 100% 0. 96[0. 56,1. 66] Total events: 89 (FDCs), 111 (SDF) Heterogeneity: Tau =0. 37; Chi =25. 57, df=11(P=0. 01); I =56. 99% Test for overall effect: Z=0. 13(P=0. 89) Test for subgroup differences: Chi =4. 11, df=1 (P=0. 04), I =75. 67% Favours FDCs 0. 01 0. 1 1 10 100 Favours SDF Analysis 2. 9. Geiter 1987 15/122 29/416 16. 77% 1. 76[0. 98,3. 18] RCTAI 1989 22/102 30/108 17. 96% 0. 78[0. 48,1. 25] Chaulet 1995 0/118 3/123 2. 94% 0. 15[0. 01,2. 85] Zhang 1996 0/102 1/103 2.
01, df=1(P=0. 94); I =0% Favours FDCs 0. 01 0. 1 1 10 100 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
82[0. 63,1. 07] Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Comparison 3. Total events: 86 (FDCs), 106 (SDF) Heterogeneity: Tau =0; Chi =2. 38, df=1(P=0. 12); I =58. 02% Test for overall effect: Z=1. 49(P=0. 14) Total (95% CI) 2301 2338 100% 0. 85[0. 72,1] Total events: 235 (FDCs), 249 (SDF) Heterogeneity: Tau =0; Chi =11. 33, df=7(P=0. 13); I =38. 19% Test for overall effect: Z=1. 97(P=0. 05) Test for subgroup differences: Chi =0. 15, df=1 (P=0. 7), I =0% Favours FDCs 0. 5 0. 7 1 1. 5 2 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 2 Relapse (ITT analysis and all losses to follow-up judged as relapse). Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Zaka-Ur-Rehman 2008 53/194 30/99 7. 07% 0. 9[0. 62,1. 31] Suryanto 2008 94/236 78/198 15. 09% 1. 01[0. 8,1. 28] Bartacek 2009 188/582 169/577 30. 19% 1. 1[0. 93,1. 31] Lienhardt 2011 140/798 144/787 25. 79% 0. 96[0. 78,1. 18] Wu 2015 26/75 37/86 6. 13% 0. 81[0. 54,1. 2] Total (95% CI) 2427 2289 100% 1. 05[0. 95,1. 16] Total events: 617 (FDCs), 545 (SDF) Heterogeneity: Tau =0; Chi =8. 2, df=9(P=0.
51); I =0% Test for overall effect: Z=0. 94(P=0. 34) Favours FDCs 0. 5 0. 7 1 1. 5 2 Favours SDF Analysis 3. 3 Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI RCTAI 1989 10/102 11/108 1. 9% 0. 96[0. 43,2. 17] Chaulet 1995 23/124 19/126 3. 35% 1. 23[0. 71,2. 14] Zhang 1996 6/104 6/105 1. 06% 1. 01[0. 34,3. 03] Teo 1999 45/155 28/155 4. 98% 1. 61[1. 06,2. 44] Su 2002 32/57 23/48 4. 44% 1. 17[0. 81,1. 7] Favours FDCs 0. 5 0. 7 1 1. 5 2 Favours SDF Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Comparison 3 Fixed-dose combinations versus single-drug formulations: sensitivity analysis by intention-to-treat (ITT), Outcome 4 Sputum smear or culture conversion at EOT (ITT analysis and all losses to follow-up judged as conversion failure). Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI Su 2002 25/57 25/48 2. 7% 0. 84[0. 56,1. 26] Suryanto 2008 188/198 152/162 16. 63% 1. 01[0. 96,1. 06] Bartacek 2009 468/582 477/577 47. 64% 0. 97[0. 92,1. 03] Wu 2015 49/75 49/86 4. 54% 1. 15[0. 9,1. 47] Total (95% CI) 1376 1176 100% 0. 99[0. 95,1. 02] Total events: 1119 (FDCs), 954 (SDF) Heterogeneity: Tau =0; Chi =4, df=6(P=0. 68); I =0% Test for overall effect: Z=0.
66(P=0. 51) Favours SDF 1 1 1 Favours FDCs Comparison 4. Study or subgroup FDCs SDF Risk Ratio Weight Risk Ratio n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI RCTAI 1989 64/102 71/108 6. 86% 0. 95[0. 78,1. 17] Zhang 1996 101/104 101/105 9. 99% 1. 01[0. 96,1. 06] Zhu 1998 224/258 79/90 11. 65% 0. 99[0. 9,1. 08] Favours SDF 1 1 1 Favours FDCs Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis (Review)Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.